AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT04009343
Drug: Artemether-lumefantrine
RxNorm normalized name: artemether-lumefantrine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Children will receive artemether-lumefantrine (20/120 mg) dosed according to weight (5 to \<15 kg: 1 tablet, 15 to \<25 kg: 2 tablets) at 0, 8, 24, 36, 48 and 60 hours. Medications will be administered according to the manufacturer's instructions.
Trial: NCT04402489
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT02157532
Drug: Best standard treatment
RxNorm normalized name: Best Choice Lice Treatment KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous r-tPA infusion or any other medical management option
Trial: NCT01099670
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT01085149
Drug: Simvastatin
RxNorm normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 10 mg simvastatin, slow release in socket of extracted tooth (single application only)
Trial: NCT03755037
Drug: Clomid, Respatio and Ethinyl estradiol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drugs were received during the menstrual cycle.
Trial: NCT02991807
Drug: RAD001
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RAD001 is formulated as tablets of 5.0 mg strength, blister-packed under aluminum foil in units of 10 tablets and dosed on a regular basis. RAD001 tablets should be opened only at the time of administration as drug is both hygroscopic and light-sensitive.~Patients will be instructed to take 4.5 mg/m2 of RAD001 orally with a glass of water at regular intervals at the same time (delete: each day) in the morning after a light, nonfat breakfast.
Trial: NCT02991807
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo will be provided as a matching tablet and will also be blister packed under aluminum foil in units of 10. Matching placebo tablets should be opened only at the time of administration as drug is both hygroscopic and light-sensitive.~Patients will be instructed to take 4.5 mg/m2 of the matching placebo orally with a glass of water at regular intervals at the same time (delete: each day) in the morning after a light, nonfat breakfast.
Trial: NCT01868269
Drug: dexamethasone and cyclophosphamide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: second step (in case of insufficient response): immunosuppressive treatment with dexamethasone and cyclophosphamide
Trial: NCT03117192
Drug: Zinc Sulfate
RxNorm normalized name: Zinc Sulfate
DrugBank: Zinc acetate (DB14487)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Zinc supplementation in syrup form
Trial: NCT02839291
Drug: intravenous or oral bone antiresorptive treatments
RxNorm normalized name: bone meal
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03323463
Drug: 5Fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: If cisplatin cannot be given at 100 mg/m2 for either cycle 1 or cycle 2, the investigator may use a regimen with carboplatin and 5-Fluorouracil in its place. 5-Fluorouracil will be given at a dose of 600 mg/m2 intravenous infusion over 24 hours daily x 4 days (total dose of 2400 mg/m2 intravenous infusion over 96 hours).
Trial: NCT03479476
Drug: Placebo Medication
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo liquid or capsules given in parallel to active medication.
Trial: NCT02443077
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT04467905
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The formulation of placebo nasal spray consists of water, sodium acetate, disodium, disodium ethylene-diamine-tetra-acetic acid (EDTA), and sulfuric acid to reproduce the same pH as the etripamil formulation.
Trial: NCT02702492
Drug: KPT-9274
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01002573
Drug: ibuprofen
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ibuprofen, 10 mg/kg
Trial: NCT01002573
Drug: acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetaminophen, 10mg/kg
Trial: NCT00698763
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsules are identical in appearance to active capsules
Trial: NCT01031212
Drug: ASA404
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered intravenously over 20 minutes weekly after chemotherapy
Trial: NCT03414502
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Starting dose of Methotrexate of 15 mg once a week plus folic acid 1mg. daily.
Trial: NCT03414502
Drug: Azathioprine
RxNorm normalized name: Azathioprine
DrugBank: Azathioprine (DB00993)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Starting dose which may be adjusted as needed at the discretion of the investigator
Trial: NCT03414502
Drug: Minocycline
RxNorm normalized name: Minocycline
DrugBank: Minocycline (DB01017)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Starting dose which may be adjusted as needed at the discretion of the investigator
Trial: NCT02106598
Drug: fluorescent cRGDY-PEG-Cy5.5-C dots
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04073173
Drug: Analgesic, Opioid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remifentanil (0.5-2 micrograms/kg/dose)
Trial: NCT02273479
Drug: Asasantin®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Asasantin® extended release (RAD-SP)
Trial: NCT02273479
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01423175
Drug: FLAMSA
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03554109
Drug: Leucovorin
RxNorm normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: L-Glutamic acid, N-\[4-\[\[(2-amino-5-formyl-1,4,5,6,7,8-hexahydro-4-oxo-6-pteridinyl)methyl\]amino\]benzoyl\]-, calcium salt
Trial: NCT00007254
Drug: Pain relief for pressure ulcers
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03554109
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 2-\[bis(2-chloroethyl)amino\]tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide monohydrate
Trial: NCT03554109
Drug: Doxorubicin HCL
RxNorm normalized name: doxorubicin HCl
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Doxorubicin HCL
Trial: NCT03175666
Drug: capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 5'-deoxy-5-fluoro-N-\[(pentyloxy) carbonyl\]-cytidine
Trial: NCT01972217
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo bid
Trial: NCT02799446
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching Placebo intravenous (IV)
Trial: NCT04240535
Drug: OnabotulinumtoxinA 50 UNT [Botox Cosmetic]
RxNorm normalized name: onabotulinumtoxinA 50 UNT [Botox Cosmetic]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injections to the Depressor Anguli Oris
Trial: NCT03175666
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 2-\[bis(2-chloroethyl)amino\]tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide monohydrate
Trial: NCT03175666
Drug: Leucovorin
RxNorm normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Calcium N-\[p-\[\[\[(6RS)-2-amino-5-formyl-5,6,7,8-tetrahydro-4-hydroxy-6-pteridinyl\]methyl\]amino\]benzoyl\]-L-glutamate (1:1)
Trial: NCT01407432
Drug: Folic acid
RxNorm normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Taking of folic acid 15 mg per day by hanging oral route during 3 at 4 months
Trial: NCT01407432
Drug: placebo of folic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Taking of placebo of folic acid by hanging oral route during 3 at 4 months
Trial: NCT03703700
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients who undergo the long-term protocol will start taking Placebo on the day of pituitary suppression, 5g three times a day (Stopping on the first 1-4 days of menstruation), and patients who undergo the antagonist protocol will start taking Placebo on the 19th to 23rd day of the previous menstruation cycle, 5g three times a day (Stopping on the first 1-4 days of menstruation). The drug will be taken till 2 weeks after transplantation. If the test result is confirmed as biochemical pregnancy (HCG\>50 IU/L), patients continue to take pills till 3 weeks after the clinical pregnancy determined by the ultrasound. If it is determined that the pregnancy test is negative, stop the drug.
Trial: NCT02170376
Drug: BIA 9-1067
RxNorm normalized name: Oatmeal 10 mg in 1 mL TOPICAL CREAM [BIA Eczema Relief]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BIA 9-1067 25 mg and 50 mg
Trial: NCT02170376
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PLC, placebo
Trial: NCT02170376
Drug: Levodopa/carbidopa
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levodopa/carbidopa, tablet 100/25 mg
Trial: NCT00578539
Drug: ARA C
RxNorm normalized name: Toxocara cati Ab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ara C (3000 mg/m2) IV every 12 hours for 6 doses (days -8 to -5)
Trial: NCT00578539
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cyclophosphamide (45mg/kg) IV once daily on day -7 and day -6
Trial: NCT02166346
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo pill 1 tablet twice daily for 8 weeks
Trial: NCT02536976
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04424134
Drug: Bromhexine and Spironolactone
RxNorm normalized name: bromhexine
DrugBank: Bromhexine (DB09019)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bromhexine 8 mg x 4 times a day x 10 days Spironolactone 50 mg x once a day x 10 days
Trial: NCT04424134
Drug: Base therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Therapy currently recommended by Ministry of Health of Russian Federation for COVID 19 treatment
Trial: NCT02289586
Drug: sedation(dezocine and midazolam)
RxNorm normalized name: Tavist Non-Sedating
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02289586
Drug: general anesthesia(midazolam, fentanyl，rocuronium，propofol and Remifentanil）
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03085004
Drug: Ethanol
RxNorm normalized name: Ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The cyst will be lavaged for 3 to 5 minutes using \>/=99% ethanol as the lavage agent prior to infusing the cyst with the paclitaxel + gemcitabine admixture.
Trial: NCT03085004
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The cyst will be lavaged for 3 to 5 minutes using normal saline as the lavage agent prior to infusing the cyst with the paclitaxel + gemcitabine admixture.
Trial: NCT00222612
Drug: Standard childhood UK ALL protocol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No additional treatment to standard protocol.
Trial: NCT00222612
Drug: Intensified treatment including Capizzi maintenance
RxNorm normalized name: Dental Resources Perio Maintenance Rinse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Augmented consolidation: vincristine, Peg-asparaginase. Capizzi maintenance: iv methotrexate and peg-asparaginase
Trial: NCT00707083
Drug: mercaptopurine
RxNorm normalized name: Mercaptopurine
DrugBank: Mercaptopurine (DB01033)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given orally
Trial: NCT00707083
Drug: methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given orally
Trial: NCT02706977
Drug: Low Dose Sinemet CR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sinemet CR (25 mg carbidopa/100 mg levodopa) will be taken by mouth twice daily for two weeks.
Trial: NCT02706977
Drug: High Dose Sinemet CR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sinemet CR (50 mg carbidopa/200 mg levodopa) will be taken by mouth twice daily for two weeks.
Trial: NCT00945958
Drug: SPARC0913
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One drop of SPARC0913 in affected eye once daily for 24 weeks
Trial: NCT00002534
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01590719
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Repeating intravenous dose until disease progression, unacceptable toxicity, or patient or physician decision to discontinue treatment
Trial: NCT04238923
Drug: Topical vancomycin paste (1g vancomycin powder + 4mL sterile saline) and Collatamp G gentamicin-eluting sponge (Azralez Pharmaceuticals; 2.0mg gentamicin sulphate/cm2 to cover wound)
RxNorm normalized name: gentamicin Topical Ointment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical vancomycin paste and gentamicin-eluting collagen sponge will be applied directly to the deep layers of the wound following reconstruction, prior to closure.
Trial: NCT01317472
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 tablet of placebo QAM (1 hour AC) for 2 months
Trial: NCT04176198
Drug: Nusivertib
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral PIM Inhibitor
Trial: NCT01354964
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02584686
Drug: Normal Saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The control group, 12 patients, will be injected with a trimix solution during penile colour Doppler assessment followed next day with a normal saline injection.
Trial: NCT00620451
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: gelatin capsule
Trial: NCT00129402
Drug: ezetimibe with simvastatin
RxNorm normalized name: ezetimibe / simvastatin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ezetimibe 10 mg plus simvastatin 10 mg once a day for six weeks, or Ezetimibe 10 mg plus simvastatin 20 mg once a day for six weeks, or Ezetimibe 10 mg plus simvastatin 40 mg once a day for six weeks
Trial: NCT00129402
Drug: simvastatin
RxNorm normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ezetimibe matching placebo plus simvastatin 10 mg once a day for six weeks, or Ezetimibe matching placebo plus simvastatin 20 mg once a day for six weeks, or Ezetimibe matching placebo plus simvastatin 40 mg once a day for six weeks
Trial: NCT01285323
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo (acetate sucrose buffer), administered intravenously (iv) once every 4 weeks for a total of 13 doses.
Trial: NCT03149679
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Chemotherapy
Trial: NCT03915886
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo tablets will be administered orally.
Trial: NCT02630823
Drug: MK-3475
RxNorm normalized name: vitamin MK 7
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03715114
Drug: GV-971
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral GV-971
Trial: NCT03715114
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Placebo
Trial: NCT04178733
Drug: LY3493269 - SC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered SC
Trial: NCT04178733
Drug: Placebo - SC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered SC
Trial: NCT04178733
Drug: LY3493269 - IV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered IV
Trial: NCT02736448
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: oral low dose of capecitabine
Trial: NCT02736448
Drug: SS-LAR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: long acting octreotide or lanreotide
Trial: NCT03940950
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline control that contains no active ingredient
Trial: NCT03169764
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 5'-deoxy-5-fluoro-N-\[(pentyloxy) carbonyl\]-cytidine
Trial: NCT03169764
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 2-\[bis(2-chloroethyl)amino\]tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide monohydrate
Trial: NCT03169764
Drug: leucovorin
RxNorm normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Calcium N-\[p-\[\[\[(6RS)-2-amino-5-formyl-5,6,7,8-tetrahydro-4-hydroxy-6-pteridinyl\]methyl\]amino\]benzoyl\]-L-glutamate (1:1)
Trial: NCT03391466
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Administered intravenously
Trial: NCT01974245
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 drops/ week for 12 weeks
Trial: NCT03785873
Drug: Leucovorin
RxNorm normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intravenous (IV) infusion
Trial: NCT03442413
Drug: 2-[18F]-FA PET/CT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2-\[18F\]FA is a highly specific radiotracer which has been used successfully to image nicotinic acetylcholine receptors in the human brain to characterize the effects of nicotine exposure (via smoking) on these receptors.
Trial: NCT03939143
Drug: DA-1229_01(A), Sugamet SR Tab 5/1000mg®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Period 1: Single oral administration of 1 tablet of test drug together with 150 mL of water containing 30 g sugar.~The wash-out for fed study is 14 days. Period 2: Single oral administration of 1 tablet of reference drug together with 150 mL of water containing 30 g sugar.
Trial: NCT03939143
Drug: Sugamet SR Tab 5/1000mg®, DA-1229_01(A)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Period 1: Single oral administration of 1 tablet of reference drug together with 150 mL of water containing 30 g sugar.~The wash-out for fed study is 14 days. Period 2: Single oral administration of 1 tablet of test drug together with 150 mL of water containing 30 g sugar.
Trial: NCT02992288
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Orally once daily for 20 weeks
Trial: NCT04636125
Drug: Doxycycline 100 MG Oral Tablet
RxNorm normalized name: DOXYCYCLINE 100 mg ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients that are undergoing a single stage revision total shoulder arthroplasty will be enrolled in this study. As is standard of care, routine cultures will be taken from predetermined areas in the shoulder. All patients will be treated with 13 days of oral Doxycycline pending culture results.
Trial: NCT03505762
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT03505762
Drug: Doxorubicin Hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT02991222
Drug: SPARC001 type I
RxNorm normalized name: collagen type I
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment type I
Trial: NCT02991222
Drug: SPARC001 type II
RxNorm normalized name: collagen type II
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment type II
Trial: NCT02991222
Drug: Reference001 type I
RxNorm normalized name: collagen type I
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrocodone-Acetaminophen
Trial: NCT02991222
Drug: Reference001 type II
RxNorm normalized name: collagen type II
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrocodone-Acetaminophen
Trial: NCT00003042
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00003042
Drug: doxorubicin hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT04214990
Drug: Placebo oral tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily placebo for 5 years
Trial: NCT04558125
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo to match supplied by Genentech, Inc. as a sterile, lyophilized powder, diluted with 10mL sterile water.
Trial: NCT01185236
Drug: simvastatin/ezetimibe
FDA approved: no
EMA approved: no
PMDA approved: no
Description: simvastatin/ezetimibe 10/20mg once daily for 12weeks
Trial: NCT00801957
Drug: hydrocortisone butyrate ointment 0.1%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: topical application
Trial: NCT03130738
Drug: 14-Day Placebo - Oil Vehicle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 14 days of 2x per day treatment with Placebo - Oil Vehicle, Study Drug base without active ingredient
Trial: NCT01033019
Drug: LDE225 0.75%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.75% cream
Trial: NCT01033019
Drug: Vehicle
RxNorm normalized name: Drug vehicle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: matching placebo cream to 0.75% LDE225 cream